Sosei and InveniAI to collaborate on AI-powered drug discovery
pharmafile | July 6, 2021 | News story | Manufacturing and Production |
Sosei Heptares and InveniAI have entered a multi-target AI-powered and GPCR-focused drug discovery collaboration.
The two companies will combine InveniAI’s validated AI-based platform, AlphaMeld, with Sosei Heptares’s GPCR structure-based drug design and early development capabilities to create therapeutics for immune diseases.
The collaboration’s aim is to identify new therapeutic product concepts for immune diseases where an AI and ML based approach can be applied to generate evidence for the role of G-protein coupled receptors (GPCRs) in relevant immunomodulatory pathways.
The goal is then to use these targets as a basis for SBDD to generate novel compounds that could improve responses to existing immunotherapies.
Dr Miles Congreve, Chief Scientific Officer, Sosei Heptares, said: “We are excited to work together with InveniAI and look forward to integrating our unique capabilities to seek and identify new links between undrugged GPCR targets and compelling disease indications.
“This collaboration has the potential to further extend our GPCR-focused drug discovery and early development capabilities. GPCRs represent an important class of pharmaceutical targets, and it is estimated that about 30% of known drugs have their mode of action through a relatively small number of GPCRs.
“This leaves a significant number of remaining GPCR targets that could be attractive for therapeutic intervention. InveniAI’s AlphaMeld platform will deconvolute the biology of disease and industrialise target discovery by rapidly unravelling connections between GPCR targets and diseases with high unmet need.”
Aman Kant, InveniAI’s Chief Business Officer, said, “We are delighted to collaborate with Sosei Heptares, an industry leader in GPCR-based therapeutic modality. We have consistently demonstrated our AI capabilities in generating clinic-ready programs across various therapeutic modalities, including biologics, small molecules, and nucleotide-based therapies.
“This collaboration will leverage InveniAI’s AI-based high-throughput discovery pipeline with Sosei Heptares’ complementary chemistry approach to deliver drug candidates efficiently, at a scale, and with an enhanced probability of clinical success.
“We continue to be excited about AlphaMeld’s potential, as numerous candidates have now progressed to various stages in clinical development as far as NDA submission.”
Lilly Subbotin
